APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-12 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IL-12 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025194 pages

Choose your research edition.

Industry ResearchIL-12 Receptor Antagonist Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-12 Receptor Antagonist Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal IL-12 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-12 Receptor Antagonist Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-12 Receptor Antagonist Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global IL-12 Receptor Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IL-12 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-12 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-12 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IL-12 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-12 Receptor Antagonist include Amgen, Biocon Biologics, Celltrion, Janssen Pharmaceuticals, Samsung Bioepis, Sandoz, Teva, Bio-Thera Solutions and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-12 Receptor Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-12 Receptor Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-12 Receptor Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-12 Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-12 Receptor Antagonist Segment by Company

Amgen

Biocon Biologics

Celltrion

Janssen Pharmaceuticals

Samsung Bioepis

Sandoz

Teva

Bio-Thera Solutions

Huadong Medicine

Qyuns Therapeutics

IL-12 Receptor Antagonist Segment by Type

Ustekinumab

Briakinumab

Other

IL-12 Receptor Antagonist Segment by Application

Plaque Psoriasis

Crohn's Disease

Ulcerative Colitis

Rheumatoid Arthritis

Other

IL-12 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-12 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-12 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-12 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-12 Receptor Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-12 Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IL-12 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IL-12 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IL-12 Receptor Antagonist Industry Trends Table 2. IL-12 Receptor Antagonist Industry Drivers Table 3. IL-12 Receptor Antagonist Industry Opportunities and Challenges Table 4. IL-12 Receptor Antagonist Industry Restraints Table 5. Global IL-12 Receptor Antagonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IL-12 Receptor Antagonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IL-12 Receptor Antagonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IL-12 Receptor Antagonist Sales Market Share by Manufacturers Table 9. Global IL-12 Receptor Antagonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IL-12 Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IL-12 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IL-12 Receptor Antagonist Manufacturers, Product Type & Application Table 13. Global IL-12 Receptor Antagonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-12 Receptor Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ustekinumab Table 17. Major Manufacturers of Briakinumab Table 18. Major Manufacturers of Other Table 19. Global IL-12 Receptor Antagonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global IL-12 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 21. Global IL-12 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 22. Global IL-12 Receptor Antagonist Sales Market Share by Type (2021-2026) Table 23. Global IL-12 Receptor Antagonist Sales Market Share by Type (2027-2032) Table 24. Global IL-12 Receptor Antagonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global IL-12 Receptor Antagonist Revenue by Type (2021-2026) & (K Units) Table 26. Global IL-12 Receptor Antagonist Revenue by Type (2027-2032) & (K Units) Table 27. Global IL-12 Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 28. Global IL-12 Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Plaque Psoriasis Table 30. Major Manufacturers of Crohn's Disease Table 31. Major Manufacturers of Ulcerative Colitis Table 32. Major Manufacturers of Rheumatoid Arthritis Table 33. Major Manufacturers of Other Table 34. Global IL-12 Receptor Antagonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global IL-12 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 36. Global IL-12 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 37. Global IL-12 Receptor Antagonist Sales Market Share by Application (2021-2026) Table 38. Global IL-12 Receptor Antagonist Sales Market Share by Application (2027-2032) Table 39. Global IL-12 Receptor Antagonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global IL-12 Receptor Antagonist Revenue by Application (2021-2026) & (K Units) Table 41. Global IL-12 Receptor Antagonist Revenue by Application (2027-2032) & (K Units) Table 42. Global IL-12 Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 43. Global IL-12 Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 44. Global IL-12 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global IL-12 Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 46. Global IL-12 Receptor Antagonist Sales Market Share by Region (2021-2026) Table 47. Global IL-12 Receptor Antagonist Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global IL-12 Receptor Antagonist Sales Forecasted Market Share by Region (2027-2032) Table 49. North America IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America IL-12 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 51. North America IL-12 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 52. Europe IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe IL-12 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 54. Europe IL-12 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific IL-12 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific IL-12 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa IL-12 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa IL-12 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 61. Global IL-12 Receptor Antagonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global IL-12 Receptor Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 63. Global IL-12 Receptor Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 64. Global IL-12 Receptor Antagonist Revenue Market Share by Region (2021-2026) Table 65. Global IL-12 Receptor Antagonist Revenue Market Share by Region (2027-2032) Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Amgen IL-12 Receptor Antagonist Product Portfolio Table 70. Amgen Recent Development Table 71. Biocon Biologics Company Information Table 72. Biocon Biologics Business Overview Table 73. Biocon Biologics IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Biocon Biologics IL-12 Receptor Antagonist Product Portfolio Table 75. Biocon Biologics Recent Development Table 76. Celltrion Company Information Table 77. Celltrion Business Overview Table 78. Celltrion IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Celltrion IL-12 Receptor Antagonist Product Portfolio Table 80. Celltrion Recent Development Table 81. Janssen Pharmaceuticals Company Information Table 82. Janssen Pharmaceuticals Business Overview Table 83. Janssen Pharmaceuticals IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Janssen Pharmaceuticals IL-12 Receptor Antagonist Product Portfolio Table 85. Janssen Pharmaceuticals Recent Development Table 86. Samsung Bioepis Company Information Table 87. Samsung Bioepis Business Overview Table 88. Samsung Bioepis IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Samsung Bioepis IL-12 Receptor Antagonist Product Portfolio Table 90. Samsung Bioepis Recent Development Table 91. Sandoz Company Information Table 92. Sandoz Business Overview Table 93. Sandoz IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Sandoz IL-12 Receptor Antagonist Product Portfolio Table 95. Sandoz Recent Development Table 96. Teva Company Information Table 97. Teva Business Overview Table 98. Teva IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Teva IL-12 Receptor Antagonist Product Portfolio Table 100. Teva Recent Development Table 101. Bio-Thera Solutions Company Information Table 102. Bio-Thera Solutions Business Overview Table 103. Bio-Thera Solutions IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Bio-Thera Solutions IL-12 Receptor Antagonist Product Portfolio Table 105. Bio-Thera Solutions Recent Development Table 106. Huadong Medicine Company Information Table 107. Huadong Medicine Business Overview Table 108. Huadong Medicine IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Huadong Medicine IL-12 Receptor Antagonist Product Portfolio Table 110. Huadong Medicine Recent Development Table 111. Qyuns Therapeutics Company Information Table 112. Qyuns Therapeutics Business Overview Table 113. Qyuns Therapeutics IL-12 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Qyuns Therapeutics IL-12 Receptor Antagonist Product Portfolio Table 115. Qyuns Therapeutics Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. IL-12 Receptor Antagonist Distributors List Table 119. IL-12 Receptor Antagonist Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. IL-12 Receptor Antagonist Product Image Figure 2. Global IL-12 Receptor Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-12 Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-12 Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Global IL-12 Receptor Antagonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IL-12 Receptor Antagonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ustekinumab Image Figure 9. Briakinumab Image Figure 10. Other Image Figure 11. Global IL-12 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global IL-12 Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global IL-12 Receptor Antagonist Sales Market Share by Type (2021-2032) Figure 14. Global IL-12 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global IL-12 Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global IL-12 Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 17. Plaque Psoriasis Image Figure 18. Crohn's Disease Image Figure 19. Ulcerative Colitis Image Figure 20. Rheumatoid Arthritis Image Figure 21. Other Image Figure 22. Global IL-12 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global IL-12 Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global IL-12 Receptor Antagonist Sales Market Share by Application (2021-2032) Figure 25. Global IL-12 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global IL-12 Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global IL-12 Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 28. North America IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America IL-12 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 30. U.S. IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe IL-12 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 35. Germany IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific IL-12 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 42. China IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa IL-12 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 50. Brazil IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile IL-12 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global IL-12 Receptor Antagonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global IL-12 Receptor Antagonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America IL-12 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 61. North America IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe IL-12 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 63. Europe IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific IL-12 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa IL-12 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. IL-12 Receptor Antagonist Value Chain Figure 69. Manufacturing Cost Structure Figure 70. IL-12 Receptor Antagonist Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ustekinumab
  • Briakinumab
  • Other
Applications
  • Plaque Psoriasis
  • Crohn's Disease
  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Other
Companies covered
  • Amgen
  • Biocon Biologics
  • Celltrion
  • Janssen Pharmaceuticals
  • Samsung Bioepis
  • Sandoz
  • Teva
  • Bio-Thera Solutions
  • Huadong Medicine
  • Qyuns Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IL-12 Receptor Antagonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IL-12 Receptor Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IL-12 Receptor Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IL-12 Receptor Antagonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IL-12 Receptor Antagonist Market Dynamics
  1. 2.1 IL-12 Receptor Antagonist Industry Trends
  2. 2.2 IL-12 Receptor Antagonist Industry Drivers
  3. 2.3 IL-12 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 IL-12 Receptor Antagonist Industry Restraints
3 IL-12 Receptor Antagonist Market by Manufacturers
  1. 3.1 Global IL-12 Receptor Antagonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IL-12 Receptor Antagonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global IL-12 Receptor Antagonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IL-12 Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-12 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IL-12 Receptor Antagonist Manufacturers, Product Type & Application
  7. 3.7 Global IL-12 Receptor Antagonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-12 Receptor Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-12 Receptor Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-12 Receptor Antagonist Tier 1, Tier 2, and Tier 3
4 IL-12 Receptor Antagonist Market by Type
  1. 4.1 IL-12 Receptor Antagonist Type Introduction
  2. 4.1.1 Ustekinumab
  3. 4.1.2 Briakinumab
  4. 4.1.3 Other
  5. 4.2 Global IL-12 Receptor Antagonist Sales by Type
  6. 4.2.1 Global IL-12 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global IL-12 Receptor Antagonist Sales by Type (2021-2032)
  8. 4.2.3 Global IL-12 Receptor Antagonist Sales Market Share by Type (2021-2032)
  9. 4.3 Global IL-12 Receptor Antagonist Revenue by Type
  10. 4.3.1 Global IL-12 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global IL-12 Receptor Antagonist Revenue by Type (2021-2032)
  12. 4.3.3 Global IL-12 Receptor Antagonist Revenue Market Share by Type (2021-2032)
5 IL-12 Receptor Antagonist Market by Application
  1. 5.1 IL-12 Receptor Antagonist Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Crohn's Disease
  4. 5.1.3 Ulcerative Colitis
  5. 5.1.4 Rheumatoid Arthritis
  6. 5.1.5 Other
  7. 5.2 Global IL-12 Receptor Antagonist Sales by Application
  8. 5.2.1 Global IL-12 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global IL-12 Receptor Antagonist Sales by Application (2021-2032)
  10. 5.2.3 Global IL-12 Receptor Antagonist Sales Market Share by Application (2021-2032)
  11. 5.3 Global IL-12 Receptor Antagonist Revenue by Application
  12. 5.3.1 Global IL-12 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global IL-12 Receptor Antagonist Revenue by Application (2021-2032)
  14. 5.3.3 Global IL-12 Receptor Antagonist Revenue Market Share by Application (2021-2032)
6 Global IL-12 Receptor Antagonist Sales by Region
  1. 6.1 Global IL-12 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-12 Receptor Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global IL-12 Receptor Antagonist Sales by Region (2021-2026)
  4. 6.2.2 Global IL-12 Receptor Antagonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IL-12 Receptor Antagonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IL-12 Receptor Antagonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IL-12 Receptor Antagonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IL-12 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IL-12 Receptor Antagonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IL-12 Receptor Antagonist Revenue by Region
  1. 7.1 Global IL-12 Receptor Antagonist Revenue by Region
  2. 7.1.1 Global IL-12 Receptor Antagonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IL-12 Receptor Antagonist Revenue by Region (2021-2026)
  4. 7.1.3 Global IL-12 Receptor Antagonist Revenue by Region (2027-2032)
  5. 7.1.4 Global IL-12 Receptor Antagonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IL-12 Receptor Antagonist Revenue (2021-2032)
  8. 7.2.2 North America IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IL-12 Receptor Antagonist Revenue (2021-2032)
  11. 7.3.2 Europe IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IL-12 Receptor Antagonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IL-12 Receptor Antagonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IL-12 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen IL-12 Receptor Antagonist Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Biocon Biologics
  8. 8.2.1 Biocon Biologics Company Information
  9. 8.2.2 Biocon Biologics Business Overview
  10. 8.2.3 Biocon Biologics IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Biologics IL-12 Receptor Antagonist Product Portfolio
  12. 8.2.5 Biocon Biologics Recent Developments
  13. 8.3 Celltrion
  14. 8.3.1 Celltrion Company Information
  15. 8.3.2 Celltrion Business Overview
  16. 8.3.3 Celltrion IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celltrion IL-12 Receptor Antagonist Product Portfolio
  18. 8.3.5 Celltrion Recent Developments
  19. 8.4 Janssen Pharmaceuticals
  20. 8.4.1 Janssen Pharmaceuticals Company Information
  21. 8.4.2 Janssen Pharmaceuticals Business Overview
  22. 8.4.3 Janssen Pharmaceuticals IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Pharmaceuticals IL-12 Receptor Antagonist Product Portfolio
  24. 8.4.5 Janssen Pharmaceuticals Recent Developments
  25. 8.5 Samsung Bioepis
  26. 8.5.1 Samsung Bioepis Company Information
  27. 8.5.2 Samsung Bioepis Business Overview
  28. 8.5.3 Samsung Bioepis IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Bioepis IL-12 Receptor Antagonist Product Portfolio
  30. 8.5.5 Samsung Bioepis Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz IL-12 Receptor Antagonist Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva IL-12 Receptor Antagonist Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Bio-Thera Solutions
  44. 8.8.1 Bio-Thera Solutions Company Information
  45. 8.8.2 Bio-Thera Solutions Business Overview
  46. 8.8.3 Bio-Thera Solutions IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Thera Solutions IL-12 Receptor Antagonist Product Portfolio
  48. 8.8.5 Bio-Thera Solutions Recent Developments
  49. 8.9 Huadong Medicine
  50. 8.9.1 Huadong Medicine Company Information
  51. 8.9.2 Huadong Medicine Business Overview
  52. 8.9.3 Huadong Medicine IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Huadong Medicine IL-12 Receptor Antagonist Product Portfolio
  54. 8.9.5 Huadong Medicine Recent Developments
  55. 8.10 Qyuns Therapeutics
  56. 8.10.1 Qyuns Therapeutics Company Information
  57. 8.10.2 Qyuns Therapeutics Business Overview
  58. 8.10.3 Qyuns Therapeutics IL-12 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qyuns Therapeutics IL-12 Receptor Antagonist Product Portfolio
  60. 8.10.5 Qyuns Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-12 Receptor Antagonist Value Chain Analysis
  2. 9.1.1 IL-12 Receptor Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-12 Receptor Antagonist Production Mode & Process
  6. 9.2 IL-12 Receptor Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-12 Receptor Antagonist Distributors
  9. 9.2.3 IL-12 Receptor Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst